title: Impact of presence of HBs antigen and anti-hepatitis C virus and anti-cytomegalovirus antibodies on transplanted kidney survival.
abstract: BACKGROUND
  Infections are one of the most common complications after organ transplantation. Viral infections such as hepatitis type B (HBV) and C (HCV) or cytomegalovirus (CMV) infections are among the most serious ones. A high frequency of HBV and HCV infections has been recognized in kidney recipients. Viral infections play a special role in graft recipients because of clinical symptoms influencing graft function and recipient survival. Immunosuppressive treatment to decrease immunological reactions after organ transplantation may increase the risk of viral infections. The aim of this study was to evaluate the impact of the presence of HBs antigen and HCV and CMV antibodies on patient and graft survivals.
  
  
  METHODS
  Two hundred one enrolled kidney transplantation patients (96 women and 105 men) were treated with the same immunosuppressive regimen. Age, sex, and viral state (HBs antigen, anti-HCV and anti-CMV antibodies) were evaluated in every patient. Statistical analysis was performed with the Gompertz model, Kaplan-Meier curves and Cox proportional hazard tests.
  
  
  RESULTS
  The presence of HBs antigen was detected in 161 patients (20.4%), HCV antibodies in 61 recipients (30.3%); and CMV antibodies in 12 patients (5.9%). Eighty-seven recipients (43.4%) were seronegative. Average recipient age was 38.5 years.
  
  
  CONCLUSIONS
  Time of graft function was independent of the presence of HBs antigen or HCV or CMV antibodies.
authors.affiliation: Department of Surgery and Transplantation, Pomeranian Medical University, ul. Powstańców Wlkp. 72, 20-111 Szczecin, Poland. jsien@poczta.onet.pl
authors.forename: J
authors.initials: J
authors.lastname: Sieńko
authors.forename: M
authors.initials: M
authors.lastname: Wiśniewska
authors.forename: K
authors.initials: K
authors.lastname: Ciechanowski
authors.forename: J
authors.initials: J
authors.lastname: Rózański
authors.forename: L
authors.initials: L
authors.lastname: Domański
authors.forename: M
authors.initials: M
authors.lastname: Myslak
authors.forename: M
authors.initials: M
authors.lastname: Kamiński
authors.forename: T
authors.initials: T
authors.lastname: Sulikowski
authors.forename: K
authors.initials: K
authors.lastname: Pabisiak
authors.forename: M
authors.initials: M
authors.lastname: Romanowski
authors.forename: A
authors.initials: A
authors.lastname: Mizerski
authors.forename: K
authors.initials: K
authors.lastname: Tejchman
authors.forename: M
authors.initials: M
authors.lastname: Nowacki
authors.forename: M
authors.initials: M
authors.lastname: Ostrowski
authors.forename: R
authors.initials: R
authors.lastname: Bohatyrewicz
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D003587:Cytomegalovirus / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival / Q000502:physiology*; D006509:Hepatitis B / Q000453:epidemiology; D006511:Hepatitis B Antigens / Q000097:blood*; D006526:Hepatitis C / Q000453:epidemiology; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology*; D008297:Male; D011183:Postoperative Complications / Q000821:virology; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D006511:Hepatitis B Antigens; D018937:Hepatitis C Antibodies